• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CMS 单剂量 80mg 静脉给药后在年轻健康志愿者体内的多粘菌素 E 和黏菌素甲磺酸钠的药代动力学。

Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers.

机构信息

INSERM ERI-23, Poitiers, France.

出版信息

Clin Pharmacol Ther. 2011 Jun;89(6):875-9. doi: 10.1038/clpt.2011.48. Epub 2011 May 4.

DOI:10.1038/clpt.2011.48
PMID:21544080
Abstract

Colistin pharmacokinetics (PK) was investigated in young healthy volunteers after a 1-h infusion of 80 mg (1 million international units (MIU)) of the prodrug colistin methanesulfonate (CMS). Concentration levels of CMS and colistin were determined in plasma and urine using a new chromatographic assay and analyzed simultaneously with a population approach after correcting the urine-related data for postexcretion hydrolysis of CMS into colistin. CMS and colistin have low volumes of distribution (14.0 and 12.4 liters, respectively), consistent with distribution being restricted to extracellular fluid. CMS is mainly excreted unchanged in urine (70% on average), with a typical renal clearance estimated at 103 ml/min-close to the glomerular filtration rate. Colistin elimination is essentially extrarenal, given that its renal clearance is 1.9 ml/min, consistent with extensive reabsorption. Colistin elimination is not limited by the formation rate because its half-life (3 h) is longer than that of CMS. The values of these pharmacokinetic parameters will serve as reference points for future comparisons with patients' data.

摘要

多粘菌素 PK 研究在年轻健康志愿者后 1 小时输注 80 毫克(100 万国际单位 (MIU))的前体药物多粘菌素甲磺酸盐 (CMS)。CMS 和多粘菌素在血浆和尿液中的浓度水平使用新的色谱分析方法测定,并在对 CMS 尿液后排泄水解校正相关数据后,采用群体方法进行同时分析。CMS 和多粘菌素的分布体积较低(分别为 14.0 和 12.4 升),与分布局限于细胞外液一致。CMS 主要以原形从尿液中排泄(平均 70%),典型的肾清除率估计为 103 ml/min-接近肾小球滤过率。多粘菌素的消除主要是肾外途径,因为其肾清除率为 1.9 ml/min,这与广泛的重吸收一致。多粘菌素消除不受形成率的限制,因为其半衰期(3 小时)长于 CMS。这些药代动力学参数的值将作为未来与患者数据进行比较的参考点。

相似文献

1
Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers.CMS 单剂量 80mg 静脉给药后在年轻健康志愿者体内的多粘菌素 E 和黏菌素甲磺酸钠的药代动力学。
Clin Pharmacol Ther. 2011 Jun;89(6):875-9. doi: 10.1038/clpt.2011.48. Epub 2011 May 4.
2
Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.静脉注射多粘菌素甲磺酸盐后大鼠体内多粘菌素甲磺酸盐和多粘菌素的药代动力学
J Antimicrob Chemother. 2004 May;53(5):837-40. doi: 10.1093/jac/dkh167. Epub 2004 Mar 24.
3
Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses.CMS 与多粘菌素 E 甲磺酸盐在大鼠体内的单次静脉 CMS 给药后的剂量范围药代动力学研究。
J Antimicrob Chemother. 2010 Aug;65(8):1753-8. doi: 10.1093/jac/dkq183. Epub 2010 May 27.
4
Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing.在接受间歇性血液透析的终末期肾病患者中,多粘菌素甲磺酸酯和形成的多粘菌素的体外清除率:给药剂量的影响。
J Antimicrob Chemother. 2015;70(6):1804-11. doi: 10.1093/jac/dkv031. Epub 2015 Feb 18.
5
Pharmacokinetics of colistin methanesulfonate (CMS) in healthy Chinese subjects after single and multiple intravenous doses.多黏菌素 E 甲磺酸盐(CMS)在健康中国受试者中单次和多次静脉给药后的药代动力学。
Int J Antimicrob Agents. 2018 May;51(5):714-720. doi: 10.1016/j.ijantimicag.2017.12.025. Epub 2018 Jan 3.
6
Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.急性肾衰竭需间歇性血液透析的重症患者中多粘菌素甲磺酸盐和多粘菌素的群体药代动力学
Antimicrob Agents Chemother. 2016 Jan 4;60(3):1788-93. doi: 10.1128/AAC.01868-15.
7
Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.在重症患者中应用9MU多粘菌素甲磺酸盐负荷剂量后的多粘菌素群体药代动力学。
Antimicrob Agents Chemother. 2015 Dec;59(12):7240-8. doi: 10.1128/AAC.00554-15. Epub 2015 Sep 14.
8
Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.在大型动物模型中,通过雾化吸入多粘菌素甲磺酸钠实现显著的靶向优势。
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.01934-16. Print 2017 Jan.
9
New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.危重症患者新的黏菌素群体药代动力学数据提示了一种替代负荷剂量的理论依据。
Antimicrob Agents Chemother. 2014 Dec;58(12):7324-30. doi: 10.1128/AAC.03508-14. Epub 2014 Sep 29.
10
Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients.雾化黏菌素甲磺酸盐在危重症患者中的药代动力学。
J Antimicrob Chemother. 2017 Sep 1;72(9):2607-2612. doi: 10.1093/jac/dkx167.

引用本文的文献

1
Development of an LC-MS/MS method for quantification of colistin and colistin methanesulfonate in human plasma and its application to stability studies and therapeutic drug monitoring.开发用于定量测定人血浆中多粘菌素和多粘菌素甲磺酸盐的液相色谱-串联质谱法及其在稳定性研究和治疗药物监测中的应用。
J Mass Spectrom Adv Clin Lab. 2025 Jun 1;37:39-48. doi: 10.1016/j.jmsacl.2025.05.001. eCollection 2025 Aug.
2
Colistin exerts potent activity against mcr+ Enterobacteriaceae via synergistic interactions with the host defense.黏菌素通过与宿主防御的协同相互作用,对携带mcr的肠杆菌科细菌发挥强大的抗菌活性。
J Clin Invest. 2025 Apr 22;135(12). doi: 10.1172/JCI170690. eCollection 2025 Jun 16.
3
A Systematic Review of Pharmacokinetic Studies of Colistin and Polymyxin B in Adult Populations.
成人人群中黏菌素和多黏菌素B药代动力学研究的系统评价
Clin Pharmacokinet. 2025 May;64(5):655-689. doi: 10.1007/s40262-025-01488-2. Epub 2025 Apr 17.
4
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections.耐碳青霉烯鲍曼不动杆菌感染的治疗方法
Drugs. 2025 Jan;85(1):21-40. doi: 10.1007/s40265-024-02104-6. Epub 2024 Nov 28.
5
Genetic predisposition and high exposure to colistin in the early treatment period as independent risk factors for colistin-induced nephrotoxicity.遗传易感性和早期治疗期间高暴露于黏菌素是黏菌素诱导的肾毒性的独立危险因素。
Clin Transl Sci. 2024 Mar;17(3):e13764. doi: 10.1111/cts.13764.
6
Unravelling the Hepatic Elimination Mechanisms of Colistin.解析多黏菌素的肝脏消除机制
Pharm Res. 2023 Jul;40(7):1723-1734. doi: 10.1007/s11095-023-03536-7. Epub 2023 May 31.
7
Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review.重症监护病房中多黏菌素使用的挑战与治疗药物监测:文献综述
Antibiotics (Basel). 2023 Feb 22;12(3):437. doi: 10.3390/antibiotics12030437.
8
Inhaled Colistimethate Sodium in the Management of Patients with Bronchiectasis Infected by : A Narrative Review of Current Evidence.吸入用硫酸多粘菌素甲磺酸钠在支气管扩张合并感染患者治疗中的应用:当前证据的叙述性综述
Infect Drug Resist. 2022 Dec 14;15:7271-7292. doi: 10.2147/IDR.S318173. eCollection 2022.
9
Neurotoxicity associated with colistin methanesulfonate treatment is enhanced by concomitant sevoflurane inhalation.与多粘菌素甲磺酸盐治疗相关的神经毒性会因同时吸入七氟醚而增强。
Toxicol Rep. 2022 Jun 2;9:1255-1260. doi: 10.1016/j.toxrep.2022.05.020. eCollection 2022.
10
Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients.硫酸黏菌素静脉给药在重症患者中的群体药代动力学及剂量优化
Front Pharmacol. 2022 Aug 29;13:967412. doi: 10.3389/fphar.2022.967412. eCollection 2022.